🤰 Breastfeeding-Compatible Antidepressant Selection Simulator

Postpartum Depression Meets the Need to Breastfeed

Placeholder lead: balancing maternal mental health treatment against infant milk exposure.

• ~13%: PPD prevalence (placeholder short stat)
• ~55%: Breastfeeding rate (6mo) (placeholder short stat)
• High: Untreated PPD risk (placeholder short stat)
• 3 compared: SSRI class options (placeholder short stat)

Why treatment choice matters here

Placeholder body text: short paragraph on weighing maternal benefit versus infant exposure risk.

Decision framework overview

Placeholder body text: clinicians weigh RID, half-life, and maternal treatment history together.

Placeholder highlight: untreated depression itself carries real risk to mother and infant.

RID — Quantifying Infant Exposure Through Breast Milk

Placeholder lead: RID expresses infant dose as percent of weight-adjusted maternal dose.

• <10%: RID safety threshold (placeholder short stat)
• 0.4–2%: Sertraline RID (placeholder short stat)
• 1–3%: Paroxetine RID (placeholder short stat)
• 6–9%: Fluoxetine RID (placeholder short stat)

How RID is calculated

Placeholder body text: infant dose (mg/kg/day) divided by maternal dose (mg/kg/day) times 100.

Why lower RID is preferred

Placeholder body text: values under 10% are generally considered compatible with breastfeeding.

Placeholder highlight: RID is one input among several, not a sole decision rule.

Sertraline — The Favored First-Line Choice

Placeholder lead: sertraline consistently shows the lowest measured RID among SSRIs.

• 0.4–2%: Typical RID (placeholder short stat)
• ~26 h: Half-life (placeholder short stat)
• Minimal: Active metabolite (placeholder short stat)
• Often undetectable: Infant serum levels (placeholder short stat)

Pharmacokinetic advantage

Placeholder body text: short elimination half-life limits steady accumulation in the infant.

Clinical track record

Placeholder body text: widely studied and frequently recommended in lactation guidelines.

Placeholder highlight: largest evidence base of any SSRI in breastfeeding studies.

Paroxetine and Fluoxetine — Weighing the Trade-offs

Placeholder lead: paroxetine is also low-RID; fluoxetine needs more caution.

• 1–3%: Paroxetine RID (placeholder short stat)
• 6–9%: Fluoxetine RID (placeholder short stat)
• 7–15 d: Fluoxetine metabolite half-life (placeholder short stat)
• Fluoxetine higher: Accumulation risk (placeholder short stat)

Paroxetine as a second option

Placeholder body text: low RID but shorter maternal half-life needs more frequent dosing.

Fluoxetine long half-life concern

Placeholder body text: norfluoxetine accumulates slowly in infants over weeks of exposure.

Placeholder highlight: fluoxetine reserved for cases with prior maternal response.

Outcome — Sertraline First-Line, Individualized Care

Placeholder lead: sertraline usually chosen; maternal response still guides therapy.

• Sertraline: First-line pick (placeholder short stat)
• Paroxetine: Backup option (placeholder short stat)
• Fluoxetine: Reserved option (placeholder short stat)
• Infant follow-up: Monitoring (placeholder short stat)

Individualized final decision

Placeholder body text: prior response to a specific SSRI can outweigh RID differences.

Ongoing infant monitoring

Placeholder body text: watch feeding, sedation, and growth after any drug is started.

Placeholder highlight: shared decision-making between clinician and mother is essential.

RID comparison at a glance